Table 2.

Summary of the European mother-child cohorts contributing to NewGeneris

CohortCountryRecruitment (years)EnrollmentBlood collectionStudy populationContribution to NewGeneris
Norwegian mother and child cohort study (22)Norway1999-2008PrenatalAt deliveryNational coverage, 52 hospitals; 100,000 pregnant womenFFQ data relevant to NewGeneris compound exposure
Bramat and BraMiljo-NewGeneris subcohortsNorway2007-2008PrenatalAt deliverySelected hospitals400 maternal-cord blood samples; FFQ data
Infancia y Medio Ambiente (23)Spain2001-2005PrenatalAt deliverySelected hospitals; 3,500200 maternal-cord blood samples; FFQ data
Infancia y Medio Ambiente-NewGeneris subcohortSpain2006-2008PrenatalAt deliverySelected hospitals
United Kingdom women's cohort study (24)United Kingdom1995-1998See*See*35,372 women across England, Wales, Scotland, and Northern IrelandFFQ data relevant to NewGeneris compound exposure
Born in Bradford study (25)United Kingdom2007-2009PrenatalAt deliveryBradford Royal Infirmary; 10,000 plannedFFQ data relevant to NewGeneris compound exposure
BiB-NewGeneris subcohortUnited Kingdom2008-2009PrenatalAt deliveryBradford Royal Infirmary; planned elective caesarian sections400 maternal-cord blood samples, mother's urine; FFQ data
Mother-child cohort (Rhea)Greece2007-2008PrenatalAt deliverySelected hospitals350 maternal-cord blood samples; father's blood and sperm; FFQ data
The Danish Biobank (DKBK)Denmark2006-2007PrenatalAt deliveryCopenhagen University Hospital100 maternal-cord blood samples; FFQ data
Danish national birth cohort (26)Denmark1997-2003PrenatalAt delivery>100,000 pregnant women across DenmarkFFQ data and selected biomarkers
  • * Women in the United Kingdom women's cohort study were not recruited in relation to pregnancy, and biological samples were not systematically collected. However, the dietary questionnaires permit investigation of NewGeneris exposures of interest in relation to outcomes in the adult children of these women.